| Quantity | Price per tablet | You save | Total price | |
|---|---|---|---|---|
| 30 | A$7.14 | - | A$214.32 | |
| 60 | A$6.84 | A$18.24 | A$410.40 | |
| 90 | A$6.37 | A$69.92 | A$573.04 | |
| 120 | A$6.16 | A$118.56 | A$738.72 | |
| 180 | A$5.88 | A$228.00 | A$1,057.92 | |
| 270 | A$5.70 | A$390.64 | A$1,538.24 | |
| 360 | A$5.52 | A$583.68 | A$1,988.16 |
Your order is carefully packed and ships within 24 hours. Here's the typical package.
Sized like a regular personal letter (24x11x0.7 cm), with no indication of its contents.
| Delivery Method | Estimated delivery |
|---|---|
| Express Free for orders over A$456.00 | Estimated delivery to Australia: 4-7 days |
| Standard Free for orders over A$304.00 | Estimated delivery to Australia: 14-21 days |
| Country | Brand Names |
|---|---|
| Australia | Exemestane Sandoz |
| Canada | Apo-Exemestane |
What Is Aromasin (Exemestane)?Aromasin, or Exemestane, is a medication commonly used in the treatment of breast cancer, specifically in postmenopausal women. It belongs to a class of drugs known as aromatase inhibitors, which block the enzyme responsible for estrogen production in the body. Estrogen can promote the growth of certain types of breast cancers, so inhibiting its production is a key strategy in hormone receptor-positive breast cancer treatment. Aromasin is often prescribed after other treatments like tamoxifen, and its central role is in preventing cancer recurrence. Like any medication, it may have side effects, and patients must discuss their medical history and potential risks with their healthcare provider before starting treatment.
Exemestane is rapidly absorbed from the gastrointestinal tract. Its bioavailability is limited by first-pass metabolism but increases when taken with food. Exemestane is widely distributed and extensively bound to plasma proteins. It is metabolized via oxidation by the cytochrome P450 isoenzyme CYP3 A4 and via reduction by aldoketoreductase. Metabolites are excreted in the urine and feces, and less than 1% of a dose is excreted unchanged in the urine. Exemestane has a terminal elimination half-life of about 24 hours.
Exemestane is a selective inhibitor of the aromatase (estrogen synthase) system, similar to formestane. It is used in the treatment of advanced breast cancer in postmenopausal women who are no longer responsive to antioestrogen therapy. It is also used for adjuvant treatment of postmenopausal women with estrogen-receptor-positive early breast cancer. After 2 to 3 years of initial adjuvant tamoxifen treatment, five years of adjuvant hormonal therapy should be given.
The recommended oral dose is 25 mg once daily, preferably after a meal. In patients receiving potent inducers of the cytochrome P450 isoenzyme CYP3A4 (such as rifampicin or phenytoin), the recommended oral dose of exemestane is 50 mg once daily after a meal.
Adverse Effects and PrecautionsThe most frequently reported adverse effects of exemestane are gastrointestinal disturbances, hot flashes, arthralgia, myalgia, sweating, fatigue, and dizziness. Other reported effects include headache, insomnia, drowsiness, depression, skin rashes, alopecia, asthenia, and peripheral and leg edema. Thrombocytopenia and leucopenia have been reported occasionally. Reductions in bone mineral density can occur with long-term use of exemestane. Density should, therefore, be assessed at the start of therapy in those with osteoporosis or at risk of it, and patients should be monitored during therapy.
The use of exemestane is contra-indicated in premenopausal women (particularly in pregnancy).
Exemestane therapy has been found to decrease bone mineral density (BMD) in postmenopausal women with early breast cancer. In one study, the decrease in BMD was seen within 6 months of switching therapy from tamoxifen and was significant at the lumbar spine and hip. In a Scandinavian study, bone mineral density loss with exemestane compared with placebo was modest from the femoral neck and not significant at the lumbar spine; however, it was noted that the changes in the placebo group were more significant than expected, possibly due to the lack of calcium and vitamin D supplementation, and that there is a high incidence of hip fracture in Scandinavia.
Patients starting exemestane therapy should be assessed for baseline bone mineral density. At the same time, those with normal BMD are considered not to need further assessment beyond lifestyle advice. Those with osteopenia should have their bone mineral density monitored and therapeutic interventions made as appropriate.
The metabolism of exemestane is mediated by the cytochrome P450 isoenzyme CYP3A4. Rifampicin, a potent inducer of CYP isoenzymes, can decrease plasma concentrations of exemestane. Use with other drugs that induce this isoenzyme may reduce the efficacy of exemestane. Exemestane should also be used cautiously with drugs that are substrates for CYP3A4 and that have a narrow therapeutic index. Significant effects on exemestane clearance by cytochrome P450 isoenzyme inhibitors are considered unlikely. Exemestane should not be given oestrogen-containing drugs as these would negate its pharmacological action.
In the battle against hormone receptor-positive breast cancer, Aromasin proves to be a potent ally, providing patients undergoing treatment with reassurance and effectiveness. Its key function in preventing cancer recurrence and raising survival rates is highlighted by its mode of action, which involves blocking aromatase and lowering estrogen levels. Aromasin is a well-received and clinically validated treatment option that represents a significant advancement in the field of oncology, offering improved prospects for those facing breast cancer.
International Nonproprietary Names (INNs) in main languages (French, Latin, Russian, and Spanish):
Synonyms: Eksemestaani; Exemestan; Exemestano; Exemestanum; FCE-24304
BAN: Exemestane
USAN: Exemestane
INN: Exemestane [rINN (en)]
INN: Exemestano [rINN (es)]
INN: Exémestane [rINN (fr)]
INN: Exemestanum [rINN (la)]
INN: Exemestane
Chemical name: 6-Methyleneandrosta-1,4-diene-3,17-dione
Molecular formula: C20H24O2 =296.4
CAS: 107868-30-4
ATC code: L02BG06
I'm in Bunbury and want to check delivery before placing my exemestane order. Can I use my postcode to see whether it can be delivered to my address?
Yes. Enter your Bunbury postcode and delivery address at checkout to check the delivery options available for your address before completing the order.
I live in Mount Isa, well outside a major city. How can I find out whether you can deliver exemestane to my area?
Add your Mount Isa address and postcode at checkout to see whether delivery is available and which options apply. Delivery timing depends on the option selected and your location.
My exemestane parcel arrived in Perth on a very hot afternoon. What should I check before I use the tablets?
Check that the carton and tablets are dry, intact and not visibly damaged, then review the label and expiry date. Exemestane should be stored at 25°C, with permitted excursions from 15°C to 30°C; if the heat exposure or product condition is uncertain, keep the package and have it checked before taking a tablet.
I'm taking exemestane and my GP has suggested oestrogen treatment for troublesome hot flushes. Can they be used together?
Oestrogen-containing treatment can reduce exemestane's intended effect because exemestane works by lowering oestrogen levels. The prescriber managing your cancer treatment should review any proposed hormone treatment before it is started.
| Active ingredient | Exemestane |
|---|---|
| Drug class | Aromatase inhibitor |
| Dosage form | Tablet |
| Available strengths | 25 mg |
| Route | Oral |
| Storage | Store at 25°C; excursions permitted from 15°C to 30°C. |
| ATC code | L02BG06 |
This product has 19 ratings, but only 4 written reviews so far. Share your experience and help other customers.
I noticed the discreet labelling on the order for exemestane.
Helpful support.
The Aromasin order arrived fine.
The larger pack, containing 270 units at 25 mg, was the practical choice.
